The Securities and Exchange Commission has extended its ongoing investigation of Northwest Biotherapeutics (NWBO) and now appears to be probing the biotech’s conduct related to its clinical trial of an experimental brain cancer treatment.
The disclosure of even more SEC scrutiny comes at a perilous time for Northwest Bio. On Friday, the company is asking shareholders to approve a financial bailout plan likely needed to stave off insolvency.
About the Author Reprints
